Cargando…

Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target

Severe acute respiratory syndrome (SARS) was the first pandemic in the 21st century to claim more than 700 lives worldwide. However, effective anti-SARS vaccines or medications are currently unavailable despite being desperately needed to adequately prepare for a possible SARS outbreak. SARS is caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Keum, Young-Sam, Jeong, Yong-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092843/
https://www.ncbi.nlm.nih.gov/pubmed/22935448
http://dx.doi.org/10.1016/j.bcp.2012.08.012
_version_ 1783510181846450176
author Keum, Young-Sam
Jeong, Yong-Joo
author_facet Keum, Young-Sam
Jeong, Yong-Joo
author_sort Keum, Young-Sam
collection PubMed
description Severe acute respiratory syndrome (SARS) was the first pandemic in the 21st century to claim more than 700 lives worldwide. However, effective anti-SARS vaccines or medications are currently unavailable despite being desperately needed to adequately prepare for a possible SARS outbreak. SARS is caused by a novel coronavirus, and one of its components, a viral helicase, is emerging as a promising target for the development of chemical SARS inhibitors. In the following review, we describe the characterization, family classification, and kinetic movement mechanisms of the SARS coronavirus (SCV) helicase—nsP13. We also discuss the recent progress in the identification of novel chemical inhibitors of nsP13 in the context of our recent discovery of the strong inhibition of the SARS helicase by natural flavonoids, myricetin and scutellarein. These compounds will serve as important resources for the future development of anti-SARS medications.
format Online
Article
Text
id pubmed-7092843
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-70928432020-03-25 Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target Keum, Young-Sam Jeong, Yong-Joo Biochem Pharmacol Review Severe acute respiratory syndrome (SARS) was the first pandemic in the 21st century to claim more than 700 lives worldwide. However, effective anti-SARS vaccines or medications are currently unavailable despite being desperately needed to adequately prepare for a possible SARS outbreak. SARS is caused by a novel coronavirus, and one of its components, a viral helicase, is emerging as a promising target for the development of chemical SARS inhibitors. In the following review, we describe the characterization, family classification, and kinetic movement mechanisms of the SARS coronavirus (SCV) helicase—nsP13. We also discuss the recent progress in the identification of novel chemical inhibitors of nsP13 in the context of our recent discovery of the strong inhibition of the SARS helicase by natural flavonoids, myricetin and scutellarein. These compounds will serve as important resources for the future development of anti-SARS medications. Elsevier Inc. 2012-11-15 2012-08-22 /pmc/articles/PMC7092843/ /pubmed/22935448 http://dx.doi.org/10.1016/j.bcp.2012.08.012 Text en Copyright © 2012 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Keum, Young-Sam
Jeong, Yong-Joo
Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title_full Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title_fullStr Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title_full_unstemmed Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title_short Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target
title_sort development of chemical inhibitors of the sars coronavirus: viral helicase as a potential target
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092843/
https://www.ncbi.nlm.nih.gov/pubmed/22935448
http://dx.doi.org/10.1016/j.bcp.2012.08.012
work_keys_str_mv AT keumyoungsam developmentofchemicalinhibitorsofthesarscoronavirusviralhelicaseasapotentialtarget
AT jeongyongjoo developmentofchemicalinhibitorsofthesarscoronavirusviralhelicaseasapotentialtarget